Treating IPF-related chronic cough with extended-release nalbuphine
Treatments studied
Part of Lungs & breathing clinical trials.
This study tests an extended-release tablet (nalbuphine) to reduce chronic coughing in people with IPF. It may help if your cough has lasted 8 weeks or more and is bothersome.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of IPF (idiopathic pulmonary fibrosis).
- You've been coughing for at least 8 weeks, and it's moderate or worse.
- Your lung function tests show your FVC (forced vital capacity) is at least 40% of normal, and your DLCO (gas exchange ability) is at least 25% of normal.
- If you take IPF medications like nintedanib or pirfenidone, your dose should have been stable for at least 6 weeks.
- You cannot have had a lung infection or been hospitalized for breathing problems in the last 2 months.
- You cannot have sleep apnea or be using a CPAP machine for sleep apnea.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an inhaled form of nintedanib (a drug that helps slow lung scarring) for people with idiopathic pulmonary fibrosis (IPF). It may be an option for those newly diagnosed or already on stable treatment.
This Phase 3 study tests whether adding lansoprazole (a stomach acid medicine) can improve outcomes for people with idiopathic pulmonary fibrosis (IPF). You may already be on IPF “anti-fibrotic” medication, and the study checks if the added lansoprazole helps, compared with placebo.
This trial tests a new medicine, BI 765423, to see if it can improve lung function in people with IPF, a lung scarring disease. You can join whether or not you are already taking standard treatments like nintedanib or pirfenidone.
This trial tests whether adding zinc and nicotinamide riboside (a vitamin B3-like supplement) to standard IPF treatment can help improve lung function. It is for people with IPF who are already seeing a lung doctor and live in certain states.
This study tests whether a new tablet called SYH2059 can help slow lung scarring in adults with idiopathic pulmonary fibrosis (IPF), a condition where lung tissue becomes thick and stiff over time. You'll take the study drug alongside your current lung treatment to see if it improves your breathing and lung function.
This trial tests whether an extended-release medication called nalbuphine can reduce coughing in people with chronic cough that hasn't improved with other treatments. You may be eligible if you've had a persistent cough for at least a year and have already tried treatments for conditions that could cause it.
Hear when a new Idiopathic Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.